atorvastatin + L-arginine + folic acid + nicorandil + nebivolol

This is a fixed-dose combination product containing five active pharmaceutical ingredients: - **Atorvastatin** is an HMG-CoA reductase inhibitor (statin) that lowers cholesterol by inhibiting the enzyme responsible for cholesterol synthesis in the liver. - **L-arginine** is a semi-essential amino acid and precursor to nitric oxide, which acts as a vasodilator and may improve endothelial function. - **Folic acid** (vitamin B9) is essential for DNA synthesis and repair, and it helps lower homocysteine levels, potentially reducing cardiovascular risk. - **Nicorandil** acts as both a nitrate donor and ATP-sensitive potassium channel opener, providing anti-anginal effects through vasodilation of coronary arteries. - **Nebivolol** is a highly selective beta-1 adrenergic receptor antagonist with additional nitric oxide-mediated vasodilatory properties; it lowers blood pressure by reducing heart rate and relaxing blood vessels. This combination targets multiple cardiovascular risk factors including hyperlipidemia, hypertension, endothelial dysfunction, angina pectoris, and elevated homocysteine. It has not been identified as an approved or widely marketed fixed-dose product but represents an approach to comprehensive cardiovascular risk management.

Other names

Endothelial Dysfunction ProtocolLAUMC-RH COVID-19 ProtocolEndothelial Dysfunction Protocol in COVID-19